Glioblastoma: bridging the gap with gene therapy
Mené dans 38 centres hospitaliers européens sur 250 patients atteints d'un glioblastome résécable, cet essai de phase III évalue, du point de vue du temps avant le décès ou avant une nouvelle intervention, l'efficacité d'une thérapie génique (sitimagene ceradenovec) suivie par du ganciclovir en injection intraveineuse
Adult glioblastoma is the most common primary brain tumour. It is characterised by substantial morbidity and mortality despite multimodal therapy with surgical resection and adjuvant radiochemotherapy as standard care. The poor prognosis is largely due to the disease's high frequency of recurrence, which is indicative of its intrinsic invasive properties into the peritumoral zone. Consequently, an unmet need exists to improve local control of glioblastoma beyond the margin of resection and to ex ...
The Lancet Oncology , commentaire, 2012